ISCT in the News

Base editing in human embryos fixes some mutations and creates others
June 9, 2026

Max Barnhart of Chemical & Engineering News covers the latest developments in human embryo base editing, with commentary from Bruce Levine, on behalf of ISCT, and David Barrett, on behalf of ASGCT, following a call for a 10-year moratorium on human heritable gene editing by The International Society for Cell & Gene Therapy (ISCT), Alliance for Regenerative Medicine (ARM), and American Society of Gene & Cell Therapy (ASGCT) 

ISCT Announces Jaap Jan Boelens, MD, PhD as inaugural Chief Medical Officer - June 1, 2026
June 1, 2026

The International Society for Cell & Gene Therapy (ISCT) is delighted to announce the appointment of Jaap Jan Boelens, MD, PhD, as the inaugural ISCT Chief Medical Officer, effective June 1st, 2026 through December 31, 2028.

As the Inaugural Chief Medical Officer, Dr. Boelens will lead the Society to strategically engage clinicians working with rapidly advancing cell and gene therapies. Part of this mandate will include developing key initiatives to solidify the ISCT clinician membership, as well as to create and spearhead programs that meet the needs of CGT expert clinicians as they advance alongside the field.

ISCT Announces Gabrielle O'Sullivan, PhD as next Chief Regulatory Officer - June 1, 2026
June 1, 2026

The International Society for Cell & Gene Therapy (ISCT) is delighted to announce the appointment of Gabrielle O'Sullivan, PhD, as the new ISCT Chief Regulatory Officer, effective June 1st, 2026 through December 31, 2028.

As Chief Regulatory Officer, Dr. O'Sullivan will lead the strategic direction of ISCT's regulatory pillar, further advancing the Society's role as a leading convening authority in global regulatory affairs for cell and gene therapies. Her leadership will help deepen ISCT's collaborations with regulatory agencies worldwide while ensuring the Society remains at the forefront of shaping frameworks that accelerate responsible innovation and patient access to advanced therapies globally.

Onyx Newsroom covers ISCT 2026 Dublin
May 6-9, 2026

Onyx Newsroom's Federico Citterich interviews a number of ISCT leaders and industry community members on site at ISCT 2026 Dublin. Hear insights from Miguel Forte, MD, PhD, Bruce Levine, PhD, Massimo Dominici, MD, and more!

ISCT Announces Inaugural CGT Clinical Applications Program for Clinical Fellows - April 21, 2026
April 21, 2026

The International Society for Cell & Gene Therapy (ISCT) Institute of Training & Development announces the launch of its inaugural Clinical Applications Program for Fellows. Exclusively for clinical fellows interested in cell and gene therapy (CGT) applications, this new educational initiative is designed to provide the highest level of clinical CGT knowledge direct from experts in the field to the next generation of clinical leaders. The program will equip clinical fellows with practical, clinic-facing skills to help advance cell and gene therapies from bench to bedside.

RegMedNet highlights top picks for ISCT 2026 Dublin
14 April, 2026

RegMedNet showcases their topics of interest from the ISCT 2026 Dublin Scientific Program - see highlighted sessions from the Scientific Annual Meeting, curated by RegMedNet. 

ISCT–JSRM 5-Year Joint Strategic Collaboration on Clinical iPSCs Launching Inaugural Joint Collaboration in Kobe, Japan - March 21, 2026
Mar 3, 2026

The International Society for Cell & Gene Therapy (ISCT), the translation-focused global community of cell and gene therapy experts and the Japanese Society for Regenerative Medicine (JSRM), advancing iPSC-based therapies, jointly announce a 5-year strategic partnership to advance iPSC-based therapies globally.

The ISCT–JSRM Joint Strategic Collaboration on Clinical iPSCs represents a landmark in the history of international regenerative medicine collaboration...